2016
DOI: 10.3917/jalmalv.125.0011
|View full text |Cite
|
Sign up to set email alerts
|

Place des thérapies complémentaires dans les soins oncologiques de support

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
1
0
1

Year Published

2016
2016
2019
2019

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 3 publications
0
1
0
1
Order By: Relevance
“…CAM is widely used, especially in the case of cancer, and prevalence is around 37.5% in France, 35.9% in Europe, or 40% in USA [12–15]. Patients hope that CAM may help them in curing the illness, improving their well-being, lessening side-effects of their treatments, improving their immune system to resist cancer and its treatments, or even prolonging their survival [11, 16, 17]. A number of systematic reviews have been conducted to assess the efficacy of CAM [15, 1822].…”
Section: Introductionmentioning
confidence: 99%
“…CAM is widely used, especially in the case of cancer, and prevalence is around 37.5% in France, 35.9% in Europe, or 40% in USA [12–15]. Patients hope that CAM may help them in curing the illness, improving their well-being, lessening side-effects of their treatments, improving their immune system to resist cancer and its treatments, or even prolonging their survival [11, 16, 17]. A number of systematic reviews have been conducted to assess the efficacy of CAM [15, 1822].…”
Section: Introductionmentioning
confidence: 99%
“…Günümüzde modern tıptaki gelişmelerle birlikte kanser tedavisinde beş yıllık sağ kalım oranlarının artmasına karşın, çok sayıda kanser hastası bu tedavilerin dışında başka arayışlara yönelmektedir. Kanser hastalarının TAT'a başvurma nedenleri arasında, bu yöntemlerin hastalığı tamamen iyileştireceğine inanılması, hastaların kemoterapinin yan etkilerinden kurtulma istekleri, hastalığa ve ilaçlara karşı immün sistemi kuvvetlendirme düşünceleri sayılabilir (9)(10)(11). Kemoterapi alan hastaların büyük bir kısmı tedavilerinin herhangi bir döneminde tamamlayıcı veya alternatif tedavi almayı düşünmektedirler (12).…”
Section: Introductionunclassified